Skip to end of metadata
Go to start of metadata

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 8 Next »

            

Working Groups – Q4 2024 Summary 


Published

We have four more published deliverables. The published deliverables this quarter are:

The Treatment Emergent Definitions Recommendations project within the Safety Analytics Working Group has published a new White Paper, 'Recommended Definition of Treatment-Emergent Adverse Events in Clinical Trials'. This White Paper defines treatment-emergent events in Phase I to IV clinical trials and integrates summary documents across therapeutic areas. The recommendations described herein were based on the authors' collective experiences and a survey conducted by the PHUSE Treatment Emergent Definitions Recommendations project team to solicit input from respondents on various TEAE scenarios for a simple clinical study design. 

The Comparing Analysis Method Implementations in Software (CAMIS) project under the Data Visualisation & Open Source Technology Working Group have just published a blog titled "A Story from the Novartis Hackathon: Industry Acceptance of the CAMIS Project". This blog talks about the CAMIS project and their involvement atthe Novartis Hackathon. 

The Best Practices in Data Standards Implementation Governance project within the Optimizing the Use of Data Standards Working Group has published a new white paper

This white paper presents the results of the survey along with feedback from informal discussions at PHUSE’s Computational Science Symposium (CSS) sessions in 2022 and 2023. The data and observations shared are intended to inform industry and identify further projects for exploration while also encouraging industry collaboration for areas which are found to be the most challenging. 

The SDTM ADaM Implementation FAQ project within the Optimizing the Use of Data Standards Working Group has published a 5 new FAQ! You can see all the FAQ's this project has answered so far via here 

Under Review 

  • No labels